This promotional information is intended for healthcare professionals based
in the UK.
If you are not a healthcare professional in the UK, click here.
For Prescribing and Adverse Event reporting information, click here.
ELIQUIS® (apixaban) is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II); treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults; and, prevention of venous thromboembolic events (VTE) in patients who have undergone elective hip or knee replacement surgery.
Please refer to the ELIQUIS Summary of Product Characteristics (SmPC) for more information.1
To download and print the checklist, click here.
FOOTNOTES
BD = Twice Daily DOAC = Direct-acting Oral Anticoagulant INR = International Normalised Ratio NVAF = Non-Valvular Atrial Fibrillation SmPC = Summary of Product Characteristics UFH = Unfractionated Heparin
REFERENCES